UE LifeSciences is a technology company.
UE LifeSciences has raised $3.0M across 1 funding round.
UE LifeSciences has raised $3.0M in total across 1 funding round.
UE LifeSciences is a med-tech company specializing in early cancer detection, particularly for breast and cervical cancers in women, through portable, non-invasive devices like iBreastExam and cervAIcal.[1][2][6] These tools enable community health workers to perform quick screenings with minimal training, targeting underserved populations in low-resource settings to address late-stage diagnoses that reduce survival rates, such as in Malaysia where 40% of breast cancer cases are detected late.[1][4][6] Serving healthcare providers globally, the company has screened over 250,000 women across 25 countries, generated over $4.2M in revenue by 2018, and secured regulatory approvals including FDA clearance and CE mark in over 12 countries.[1][3][6]
Founded in 2009 in Philadelphia, Pennsylvania, UE LifeSciences emerged from technology developed by scientists and doctors at Drexel University, including a patented Piezoelectric Sensor Array for measuring tissue elasticity to detect breast tumors.[1][2][3] Entrepreneur Mihir Shah, a Drexel alumnus motivated by his family's cancer experiences, licensed the sensor tech in 2010 and founded the company to improve global diagnostics.[3] Key milestones include a 2012 Pennsylvania CURE grant of $878K for prototyping, FDA approval in 2015 via the University City Science Center's Digital Health Accelerator, and early commercialization in India where breast cancer survival is only 50% at diagnosis.[3][6] The company has since expanded with offices in India, Malaysia, and Colombia, employing over 50 people.[3][6]
UE LifeSciences rides the wave of mobile health (mHealth) and women's health tech, addressing global disparities in cancer screening where late detection drives high mortality in emerging markets like India and Southeast Asia.[1][3][4][6] Timing aligns with rising demand for equitable, low-cost diagnostics amid aging populations and resource constraints in low/middle-income countries, amplified by post-pandemic telehealth shifts and AI-enhanced devices.[2][6] Market forces favoring them include regulatory wins (FDA, CE), partnerships with giants like GE and government PSUs in India, and a $5.16M funding base enabling pilots in 25 countries.[1][3][6] They influence the ecosystem by standardizing community-based screening, boosting early intervention survival rates, and pioneering sensor tech from academia to scale in preventive care.[3][4][7]
UE LifeSciences is poised for accelerated global expansion through deepened partnerships in Latin America, Africa, and Asia, leveraging its validated tech stack to integrate AI-driven tools like cervAIcal into national health programs.[3][6] Trends like AI in diagnostics, decentralized care, and women's health equity will propel growth, potentially multiplying revenue via volume screenings and new products like OrCA. Their influence may evolve from niche innovator to ecosystem shaper, rewriting cancer outcomes in underserved regions by making early detection as routine as a clinic visit.[4][6] This positions them as a vital player in accessible med-tech, directly tackling the late-detection crisis that UE LifeSciences was built to solve.
UE LifeSciences has raised $3.0M in total across 1 funding round.
UE LifeSciences's investors include 3one4 Capital.
UE LifeSciences has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series A in September 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2015 | $3.0M Series A | 3one4 Capital |